Table 2.
Subject number | Postnatal opioid treatment for NOWS | Days of postnatal opioid exposure | Secondary medications for NOWS | Highest Finnegan score | Average Finnegan score on day of life 3 |
---|---|---|---|---|---|
1 | methadone | 9 | 16 | 8 | |
2 | buprenorphine | 6 | 13 | 7.6 | |
3 | 17 | 7.9 | |||
4 | methadone | 10 | 12 | 8 | |
5 | buprenorphine | 10 | phenobarbital | 15 | 9.8 |
6 | 12 | 9.3 | |||
7 | 4 | 3 | |||
8 | 8 | 1.6 | |||
9 | 13 | 7.4 | |||
10 | buprenorphine | 14 | 16 | 7.6 | |
11 | 6 | 3 | |||
12 | 13 | 2.5 | |||
13 | buprenorphine | 6 | clonidine | 17 | 5.3 |
14 | 10 | 5.3 | |||
15 | 2 | 0.25 | |||
16 | 2 | 0.25 | |||
17 | 7 | 1.9 | |||
18 | 10 | 6.4 | |||
19 | 13 | 8.5 |